In vitro diagnostics specialist bioMérieux has announced a 21% drop in net income (group share) to 358 million euros for 2023, but operating income of 610 million euros (or 16.6% of sales), up 2% on an organic basis.
At 3.67 billion euros, sales were up 6.6% on an organic basis, 'thanks to an excellent performance by Biofire's microbiology and non-breathing panel sales, and to a lower-than-expected decline in Biofire's breathing panel sales'.
At the Annual General Meeting on May 23, the Board of Directors will propose a stable dividend of 0.85 euros per share for the past year, representing a payout ratio of 28% of net income, higher than usual.
For 2024, bioMérieux expects, at constant exchange rates and scope of consolidation, an increase in operating income before non-recurring items of at least 10%, and sales growth of between 6 and 8%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).